

Nielka P Van Erp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7924637/publications.pdf>

Version: 2024-02-01

112
papers

3,021
citations

186265
28
h-index

175258
52
g-index

112
all docs

112
docs citations

112
times ranked

3791
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical pharmacokinetics of tyrosine kinase inhibitors. <i>Cancer Treatment Reviews</i> , 2009, 35, 692-706.	7.7	437
2	Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity. <i>Journal of Clinical Oncology</i> , 2009, 27, 4406-4412.	1.6	177
3	Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib. <i>Clinical Cancer Research</i> , 2011, 17, 620-629.	7.0	150
4	Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3495-3503.	3.6	146
5	Effect of Milk Thistle (<i>Silybum marianum</i>) on the Pharmacokinetics of Irinotecan. <i>Clinical Cancer Research</i> , 2005, 11, 7800-7806.	7.0	115
6	Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. <i>Clinical Cancer Research</i> , 2007, 13, 7394-7400.	7.0	107
7	Mitotane has a strong and a durable inducing effect on CYP3A4 activity. <i>European Journal of Endocrinology</i> , 2011, 164, 621-626.	3.7	99
8	mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. <i>International Journal of Cancer</i> , 2016, 138, 2312-2321.	5.1	76
9	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1369-1380.	3.5	74
10	Individualized dosing of tyrosine kinase inhibitors: are we there yet?. <i>Drug Discovery Today</i> , 2015, 20, 18-36.	6.4	72
11	A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 937, 33-43.	2.3	71
12	Mammalian target of rapamycin inhibitor-associated stomatitis. <i>Future Oncology</i> , 2013, 9, 1883-1892.	2.4	68
13	Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncology</i> , 2019, 20, e200-e207.	10.7	68
14	Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1479-1485.	7.0	63
15	Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2195-2204.	2.4	61
16	Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 258-273.	2.4	56
17	Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2525.	3.6	55
18	Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 331-338.	2.0	48

#	ARTICLE	IF	CITATIONS
19	Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. <i>Drug Discovery Today</i> , 2016, 21, 962-976.	6.4	46
20	Marginal increase of sunitinib exposure by grapefruit juice. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 695-703.	2.3	45
21	Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 122-129.	2.4	41
22	Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 219-230.	3.1	36
23	Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 293-303.	3.5	35
24	Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS. <i>Biomedical Chromatography</i> , 2020, 34, e4758.	1.7	35
25	Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 63-71.	2.3	34
26	Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group's Therapeutic Drug Monitoring Protocol for a Prospective Study. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 561-567.	2.0	33
27	Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1105, 76-84.	2.3	33
28	Simultaneous quantitation of abiraterone, enzalutamide, N -desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 138, 197-205.	2.8	29
29	Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1110-1111, 15-24.	2.3	28
30	Dried blood spot analysis for therapeutic drug monitoring of pazopanib. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1344-1350.	2.0	26
31	The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (<sc>DIET</sc> Study). <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1076-1082.	4.7	26
32	Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite <sc>SU</sc>12662. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 809-819.	2.4	25
33	Using mRNA expression profiling to determine anticancer drug efficacy. <i>Cytometry</i> , 2002, 47, 66-71.	1.8	24
34	Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 87-96.	2.3	24
35	Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1994-2001.	2.4	24
36	Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 149, 106-113.	2.8	23

#	ARTICLE	IF	CITATIONS
37	Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC. <i>Clinical Cancer Research</i> , 2008, 14, 8308-8313.	7.0	20
38	Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma. <i>Biomedical Chromatography</i> , 2017, 31, e3986.	1.7	20
39	Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 401-411.	4.4	20
40	Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2019, 58, 651-658.	3.5	20
41	Myelosuppression by sunitinib is flt-3 genotype dependent. <i>British Journal of Cancer</i> , 2010, 103, 757-758.	6.4	19
42	Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 47-58.	2.4	19
43	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 714-729.	3.0	18
44	The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 326-335.	2.4	18
45	A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1447-1456.	3.5	17
46	Monitoring Protein-Unbound Valproic Acid Serum Concentrations in Clinical Practice. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 269-272.	2.0	17
47	Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal. <i>Acta Oncologica</i> , 2017, 56, 1238-1240.	1.8	16
48	Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 457-463.	2.3	15
49	Successful Treatment of Renal Cell Carcinoma With Sorafenib After Effective but Hepatotoxic Sunitinib Exposure. <i>Journal of Clinical Oncology</i> , 2013, 31, e83-e86.	1.6	13
50	Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. <i>BMC Cancer</i> , 2014, 14, 575.	2.6	13
51	The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 501-507.	2.0	13
52	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 222-229.	2.0	11
53	Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane. <i>Targeted Oncology</i> , 2019, 14, 441-451.	3.6	11
54	Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer. <i>BMC Cancer</i> , 2022, 22, 228.	2.6	11

#	ARTICLE	IF	CITATIONS
55	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. <i>Journal of Translational Medicine</i> , 2016, 14, 88.	4.4	10
56	Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. <i>Targeted Oncology</i> , 2018, 13, 641-648.	3.6	10
57	Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [18 F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid tumours: All that glitters is not gold. <i>European Journal of Cancer</i> , 2016, 56, 54-58.	2.8	9
58	A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1179-1185.	2.3	9
59	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. <i>Molecular Oncology</i> , 2021, 15, 2453-2465.	4.6	9
60	Promising management of pazopanib-induced liver toxicity. <i>Acta Oncologica</i> , 2015, 54, 1064-1066.	1.8	8
61	Fatal heart failure in a young adult female sarcoma patient treated with pazopanib. <i>Acta Oncologica</i> , 2017, 56, 1233-1234.	1.8	8
62	Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas. <i>Anticancer Research</i> , 2019, 39, 1309-1316.	1.1	8
63	High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review. <i>Cancer Treatment Reviews</i> , 2021, 97, 102171.	7.7	8
64	Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer. <i>International Journal of Cancer</i> , 2022, 150, 308-316.	5.1	8
65	The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. <i>International Journal of Cancer</i> , 2021, 148, 2799-2806.	5.1	8
66	Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2312-2314.	2.4	7
67	A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1064-1067.	2.4	7
68	The Combination of Enzalutamide and Opioids: A Painful Pitfall?. <i>European Urology</i> , 2019, 75, 351-352.	1.9	7
69	Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 191-203.	3.5	7
70	Is rectal administration an alternative route for imatinib?. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 623-624.	2.3	6
71	Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1279-1281.	1.9	6
72	Dose Reduction May Jeopardize Efficacy of Abiraterone Acetate. <i>Journal of Clinical Oncology</i> , 2018, 36, 3062-3064.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. <i>Pharmaceutical Research</i> , 2019, 36, 33.	3.5	6
74	The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2399-2404.	2.4	5
75	Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?. <i>Pharmaceutical Research</i> , 2019, 36, 163.	3.5	5
76	The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 753-760.	2.3	5
77	The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1170-1178.	2.4	5
78	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 6279.	3.7	5
79	The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study. <i>Targeted Oncology</i> , 2018, 13, 363-370.	3.6	4
80	Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. <i>Pharmaceutical Research</i> , 2019, 36, 181.	3.5	4
81	Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 146-150.	2.0	4
82	Pressurized Intraperitoneal Aerosol Chemotherapy: The Road from Promise to Proof. <i>Clinical Cancer Research</i> , 2021, 27, 1830-1832.	7.0	4
83	Poorly specified fasting conditions in clinical research could lead to treatment failure. <i>Lancet Oncology</i> , 2017, 18, 571-573.	10.7	3
84	Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study. <i>Annals of Oncology</i> , 2019, 30, v161.	1.2	3
85	Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 141-150.	2.3	3
86	Food intervention to make therapy with pazopanib more patient-friendly and affordable.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11040-11040.	1.6	3
87	Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113393.	5.6	3
88	Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy-naïve patient: a case report. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 165-168.	2.3	2
89	Early metabolic response as predictor for treatment outcome of pazopanib in patients with metastatic soft tissue sarcomas (the PREDICT study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11555-11555.	1.6	2
90	A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?. <i>Journal of Clinical Oncology</i> , 2019, 37, 4564-4564.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, , 1.	2.3	2
92	On-treatment plasma ctDNA fraction and treatment outcomes in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5051-5051.	1.6	2
93	A successful approach to overcome imatinib-induced skin toxicity in a GIST patient. <i>Anti-Cancer Drugs</i> , 2016, 27, 576-579.	1.4	1
94	Reply to "Hyperthermic intraperitoneal chemotherapy with oxaliplatin" Still not standard of care for patients with colorectal peritoneal metastases" by Julianov and Saroglu. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1848-1849.	2.4	1
95	Intravenous lidocaine affects oxaliplatin pharmacokinetics in simultaneous infusion. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1850-1856.	0.9	1
96	Dose finding of oncolytic combination therapy: Essential to secure the patient's quality of life. <i>European Journal of Cancer</i> , 2021, , .	2.8	1
97	Development and validation of a bioanalytical assay on LC/MS/MS to quantify enzalutamide and N-desmethylenzalutamide in human plasma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 330-330.	1.6	1
98	The impact of gastric acid suppressive agents on pazopanib exposure.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16076-e16076.	1.6	1
99	Ritonavir-boosted antiretroviral therapy with paclitaxel: will it lead to boosted toxicity?. <i>Aids</i> , 2022, 36, 322-323.	2.2	1
100	Fasting conditions in clinical oncology trials and drug labelling " Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e507.	10.7	0
101	Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution " Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e290.	10.7	0
102	Bone sarcoma during pregnancy: an example of personalized multidisciplinary care. <i>Acta OncolÃ³gica</i> , 2019, 58, 128-131.	1.8	0
103	Comments on "Systemic exposure of oxaliplatin and docetaxel in gastric patients with peritonitis carcinomatosa treated with intraperitoneal hyperthermic chemotherapy" <i>European Journal of Surgical Oncology</i> , 2021, 47, 1216-1217.	1.0	0
104	Analytical challenges in quantitative analysis (LC/MS/MS) of abiraterone: A validated assay to determine abiraterone in human plasma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 329-329.	1.6	0
105	Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9540-9540.	1.6	0
106	Everolimus exposure and early metabolic response as predictors for treatment outcomes in breast cancer patients treated with everolimus and exemestane.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1062-1062.	1.6	0
107	Development of an online drug-drug interaction resource to support safe prescription of oncolytics.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18574-e18574.	1.6	0
108	Does a food intervention makes abiraterone treatment affordable?. <i>Journal of Clinical Oncology</i> , 2019, 37, e16523-e16523.	1.6	0

#	ARTICLE	IF	CITATIONS
109	The effect of gastrectomy in regorafenib treated GIST patients on outcome and drug exposure.. Journal of Clinical Oncology, 2019, 37, e22511-e22511.	1.6	0
110	Abstract C079: Effect of food on the pharmacokinetics of high dose intermittent sunitinib in patients with advanced solid tumors. , 2019, , .		0
111	Abstract 1413: Exploring the prognostic value of microRNAs and drug exposure in patients with metastatic castration resistant prostate cancer treated with abiraterone: a prospective observational study. , 2020, , .		0
112	Is age just a number? A population pharmacokinetic study of gemcitabine. Cancer Chemotherapy and Pharmacology, 2022, 89, 697-705.	2.3	0